Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

AI-Driven Hip Exoskeleton Control for Diverse Users and Walking Tasks

10. november 2026 opdateret af: Inseung Kang, Carnegie Mellon University

AI-Driven Hip Exoskeleton Control Framework That Rapidly Generalizes to a Broad Range of Users and Real-World Locomotor Tasks

The goal of this clinical trial is to evaluate the feasibility of a prototype artificial intelligence (AI)-based controller for a lightweight hip exoskeleton across a broad range of users, including healthy younger adults (18-39 years) and older adults (65 years and older). The main questions it aims to answer are:

  • Can the AI-based controller accurately estimate gait phase in real time across younger and older adults?
  • How does hip exoskeleton assistance change walking energy cost, mechanics, and muscle activity?

Researchers will compare walking with powered hip exoskeleton assistance to walking without the exoskeleton and walking while wearing the exoskeleton with no assistance (zero torque).

Participants will:

  • Complete a short screening and frailty assessment
  • Walk on a treadmill under different conditions with and without the hip exoskeleton during 2 to 5 lab visits
  • Wear motion capture markers, muscle activity (EMG) sensors, and a mask that measures breathing to estimate energy use

Studieoversigt

Status

Rekruttering

Detaljeret beskrivelse

This study is funded by the National Institute of Biomedical Imaging and Bioengineering (R21EB037268) and conducted at the University of Texas at Austin in collaboration with Carnegie Mellon University. The CMU Hip Exoskeleton is a research prototype with powered hip joints for flexion and extension (peak torque 18 Nm, total weight 3.5 kg). Its controller uses joint angle and user-state estimates to command assistive torque, limited to less than 0.2 Nm/kg (at most about 30% of typical biological hip moments during walking), so it supplements rather than overrides the user's own muscle effort.

During each visit, participants walk on a force-instrumented treadmill at 1.25 m/s with safety harness and handrails. Researchers record whole-body motion capture, ground reaction forces, inertial measurement unit data, lower-limb electromyography, and metabolic energy expenditure via open-circuit indirect calorimetry. Walking conditions include no exoskeleton, exoskeleton worn with zero torque, and powered exoskeleton assistance. Outcomes will be compared across conditions and between younger and older adults using repeated-measures statistical analysis.

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

16

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Studiesteder

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ja

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • Age 18 to 39 years (younger adult group) or 65 years and older (older adult group)
  • Willing and able to provide informed consent
  • Able to walk independently without assistance
  • No known cardiovascular, metabolic, or renal disease, and no signs or symptoms suggestive of such disease
  • Cleared for light- to moderate-intensity exercise without the need for medical clearance under American College of Sports Medicine (ACSM) preparticipation screening guidelines

Exclusion Criteria:

  • Age 40 to 64 years
  • Leg surgery within the past 5 years
  • Orthopedic disability that could impair movement or limit participation in the exercise protocol
  • Neurologic disorder that may affect neuromuscular function or gait (e.g., stroke, Parkinson's disease, peripheral neuropathy, traumatic brain injury)
  • Known metabolic or cardiovascular disease (hypertension alone is not exclusionary), or requiring medical clearance under ACSM guidelines without having obtained it
  • Metal implants in the lower extremities, cardiac pacemaker, or other implanted electronic device
  • Pregnancy
  • History of seizure disorder or fainting (syncope)

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Enhedens gennemførlighed
  • Tildeling: N/A
  • Interventionel model: Enkelt gruppeopgave
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Hip Exoskeleton Walking

Healthy younger adults (18-39 years) and older adults (65+ years) walk on an instrumented treadmill under multiple conditions across 2-5 lab visits: no exoskeleton, wearing the CMU Hip Exoskeleton with zero torque, and with powered assistance from the AI-driven hip exoskeleton controller (assistance limited to <0.2 Nm/kg). The primary objective is to evaluate real-time gait phase estimation accuracy of the prototype controller across users; metabolic cost, biomechanics, and muscle activity are recorded as secondary measures.

A lightweight (3.5 kg) research hip exoskeleton developed at Carnegie Mellon University with powered hip flexion/extension joints, a backpack-mounted computer and battery, and thigh and waist interfaces secured with straps. An AI-driven controller estimates the user's gait state from joint angle and wearable sensor data and commands assistive hip torque in real time, limited to <0.2 Nm/kg (peak device torque 18 Nm). Participants walk on a treadmill with powered assistance, with the device worn at zero torque, and without the device. The device was determined by the UT Austin IRB to be a non-significant risk device.

Andre navne:
  • CMU Hip Exoskeleton

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Gait Phase Estimation Error of the AI-Driven Hip Exoskeleton Controller
Tidsramme: Day 1

Root-mean-square error (RMSE) between the controller's real-time gait phase estimate and ground-truth gait phase derived from force-instrumented treadmill data during powered hip exoskeleton walking, reported as percent of the gait cycle (%). Used to evaluate feasibility of the prototype controller across younger and older adult users.

Day 1

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Net Metabolic Power During Powered Hip Exoskeleton Walking
Tidsramme: Day 1

Net metabolic power (W/kg), measured by open-circuit indirect calorimetry with resting value subtracted, during treadmill walking at 1.25 m/s with powered hip exoskeleton assistance.

Day 1
Peak Hip Joint Moment During Powered Hip Exoskeleton Walking
Tidsramme: Day 1

Peak biological hip extension moment (Nm/kg), computed from motion capture and force-instrumented treadmill data, during treadmill walking with powered hip exoskeleton assistance.

Day 1
Lower-Limb Muscle Activity During Powered Hip Exoskeleton Walking
Tidsramme: Day 1

Average electromyography (EMG) amplitude normalized to maximum voluntary contraction (%MVC), averaged across eight recorded lower-limb muscles, during treadmill walking with powered hip exoskeleton assistance.

Day 1

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Efterforskere

  • Ledende efterforsker: Inseung Kang, PhD, Carnegie Mellon University

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

6. august 2026

Primær færdiggørelse (Anslået)

31. august 2027

Studieafslutning (Anslået)

31. januar 2028

Datoer for studieregistrering

Først indsendt

3. november 2026

Først indsendt, der opfyldte QC-kriterier

10. november 2026

Først opslået (Faktiske)

16. november 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

16. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

10. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • STUDY2026_00000477
  • R21EB037268 (U.S. NIH-bevilling/kontrakt)

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

JA

IPD-planbeskrivelse

De-identified individual participant data underlying published results will be shared, including biomechanics (motion capture, ground reaction forces), electromyography, metabolic, and exoskeleton sensor/controller data, along with participant characteristics (age group, sex, height, mass). Identifiable information, including video recordings, will not be shared.

IPD-delingstidsramme

Data will be made available no later than the time of associated publication or the end of the award period, whichever comes first, and will remain available for at least 5 years.

IPD-delingsadgangskriterier

De-identified data and supporting information will be deposited in a public data repository and made openly available to researchers without restriction, subject to the repository's terms of use.

IPD-deling Understøttende informationstype

  • STUDY_PROTOCOL
  • ANALYTIC_CODE

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ja

produkt fremstillet i og eksporteret fra U.S.A.

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner